Trial of S-1 in Combination With Sorafenib for Patients With Advanced Hepatocellular Carcinoma
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
In preclinical studies, 5-fluorouracil, one of the active metabolites of S-1, showed synergistic effect to sorafenib in human colon carcinoma cell lines. Therefore, sorafenib combined with S-1 might be more effective treatment for patients with advanced HCC than sorafenib monotherapy. The investigators propose to conduct a phase I study to determine maximal tolerated dose (MTD) of S-1 in combination with fixed dose of sorafenib in patients with advanced HCC
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study:
18 Years and older (Adult, Older Adult)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Patients with histologically confirmed hepatocellular carcinoma (HCC) or a combination of radiologically compatible finding to HCC, alpha-fetoprotein>400ng/mL and liver cirrhosis
Inoperable disease as defined by
Localized disease in a portion of the liver that doses not allow the possibility of complete surgical removal of the tumor with a clear resection margin OR
Presence of extra-hepatic disease OR
Main portal vein or hepatic vein involvement (invasion or tumor thrombus) OR
The HCC must not be amenable to intra-arterial therapy or local ablative therapy
Minimum life expectancy of 12 weeks
ECOG Performance Status of 0-1
Adequate bone marrow, liver and renal function as assessed by the following laboratory requirements to be conducted within 7 days prior to screening:
Absolute neutrophil count (ANC) >1,500/mm3
Platelet count > 75,000/μl
Total bilirubin < 1.5 times the upper limit of normal
ALT and AST <5 x upper limit of normal
Albumin >= 3g/dL
PT-INR/PTT <1.5 x upper limit of normal
Serum creatinine < 1.5 x upper limit of normal or Creatinine clearance >=50mL/min
Signed and dated informed consent before the start of specific protocol procedures.
Decompensated cirrhosis or stage C according to the Child-Pugh Classification
Chemo-embolization within 8 weeks of inclusion
Other concomitant anticancer agent, including Tamoxifen and Interferon
History of cardiac disease: congestive heart failure >NYHA class 2; active CAD (MI more than 6 mo prior to study entry is allowed); cardiac arrhythmias requiring anti-arrhythmic therapy (beta blockers or digoxin are permitted) or uncontrolled hypertension.
History of HIV infection
Active clinically serious infections (> grade 2 CTCAE version 3.0)
Symptomatic metastatic brain or meningeal tumors
Patients with seizure disorder requiring medication (such as steroids or anti-epileptics)
History of organ allograft
Patients with evidence or history of bleeding diathesis
Patients undergoing renal dialysis
Radiotherapy during study or within 4 weeks of start of study drug.
Major surgery within 4 weeks of start of study
Autologous bone marrow transplant or stem cell rescue within 4 months of study
Prior exposure to the study drug.
Pregnant or breast-feeding patients. Women of childbearing potential must have a negative pregnancy test performed within 7 days of the start of treatment. Both men and women enrolled in this trial must use adequate barrier birth control measures during the course of the trial (and men for at least 3 months after last administration of study medication).
Substance abuse, medical, psychological or social conditions that may interfere with the patient's participation in the study or evaluation of the study results
Any condition that is unstable or could jeopardize the safety of the patient and their compliance in the study
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Digestive System Neoplasms
Neoplasms by Site
Digestive System Diseases
Protein Kinase Inhibitors
Molecular Mechanisms of Pharmacological Action
Vitamin B Complex
Physiological Effects of Drugs